サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Top 20 Pharmaceutical Wholesale & Distribution Organizations 2018

トップ20医薬品卸&流通組織2018

レポート概要

レポートの詳細

医薬品卸および流通市場は活気に満ちており、大勢の人々に命を救う医薬品をタイムリーに届けています。この市場は大規模で、予測期間中は多くの成長、拡大の機会があります。医薬品卸市場の確立を後押ししたのは、研究開発やマーケティングのコアコンピタンスに注力するために流通を卸に委託したいと考えていたメーカーでした。同時に、病院はこの分野における投資を減らすために在庫管理を外部に委託しました。これらの要因によって包括的な卸、流通サービスの需要が増大しました。

このレポートがもたらすメリット:

読み進めるにつれてこのセクターに出現するビジネスチャンスを掴む方法が明らかになります。

この229ページのレポートに132の表、グラフを掲載‐全て他のどこでも入手できないものです。

このレポートを利用することによって、世界の医薬品卸および流通組織について明確で詳細な見識を得ることができます。また市場の主な推進要因と課題が明らかになります。

レポート詳細

目次

1. Report Overview
1.1 Global Pharma Wholesale and Distribution Industry and Market Overview
1.2 How This Report Delivers
1.3 Questions Answered by This Analytical Report
1.4 Who is This Report For?
1.5 Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain

2. Introduction to Pharma Wholesale and Distribution
2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
2.1.1 Full-Line Wholesalers (FLWs)
2.1.2 Short-Line Wholesalers (SLWs)
2.2 The Chain of Distribution: Wholesalers vs. Logistic Service Providers
2.2.1 Secondary Wholesalers
2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
2.2.3 Major Wholesalers: Distribution of a Large Number of Products to Generate High Profits
2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
2.2.5 Pharmacy Benefit Managers
2.3 Generative Revenue and Profit
2.3.1 Forward Buying to Avoid Price Increases
2.3.2 Fee-for-Service: A Clear Pricing Structure
2.3.2.1 Inventory Management Agreements
2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases
2.3.4 Reimbursement and Wholesalers
2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments
2.3.6 Parallel Trade: Different Attitudes in Europe and the US

3. The World Pharmaceutical Wholesale and Distribution Market: 2016-2027
3.1 The World Pharmaceutical Wholesale and Distribution Market in 2016, Restricted by Government Price Reductions and Generic Substitution
3.2 The Pharmaceutical Wholesale and Distribution Industry: World Market Forecast, 2016-2027
3.3 Branded and Generic Drugs: Revenue vs. Profit, 2016-2027
3.3.1 Branded and Generic Drugs: Revenue Generation, 2016
3.3.2 Branded Drugs: Revenue Forecast, 2016-2027
3.3.3 Generic Drugs: Revenue Forecast, 2016-2027

4. Leading Pharma Wholesalers and Distributors In 2018: Current and Future Performace
4.1 McKesson: The Oldest and Largest Healthcare Services Company in the US
4.1.1 McKesson: Historical Performance, 2007-2017
4.1.2 Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses
4.1.3 McKesson: Revenue Forecast, 2018-2028
4.2 Cardinal Health: The World’s Third Largest Pharma Wholesaler
4.2.1 Cardinal Health: Historical Performance, 2010-2017
4.2.2 Will CVS Joint Venture and Acquisitions Stimulate Future Growth?
4.2.3 Cardinal Health: Revenue Forecast, 2018-2028
4.3 AmerisourceBergen: Third Largest Global Pharma Wholesaler and Distributor
4.3.1 AmerisourceBergen: Historical Performance, 2018
4.3.2 Will Contracts with Walgreens and Alliance Boots Drive Future Growth?
4.3.3 AmerisourceBergen: Revenue Forecast, 2018-2028
4.4 Walgreens Boots Alliance: The Largest Drugstore Chain in the US and Global Wholesale and Distribution Network
4.4.1 Walgreens Boots Alliance: Historical Performance, 2011-2017
4.4.2 Acquisitions and Future Strategies of Walgreens Boots Alliance
4.4.3 Walgreens Boots Alliance: Revenue Forecast, 2018-2028
4.5 MEDIPAL HOLDINGS CORPORATION: Japan’s Leading Pharmaceutical Wholesaler
4.5.1 MEDIPAL HOLDINGS CORPORATION: Historical Performance, 2007-2017
4.5.2 Future Strategies of MEDIPAL HOLDINGS CORPORATION: Revised Business Portfolio with Diverse Sources of Earnings
4.5.3 MEDIPAL HOLDINGS CORPORATION: Revenue Forecast, 2018-2028
4.6 Phoenix Group: Biggest European Wholesalers
4.6.1 The PHOENIX Group: Historical Performance, 2011-2015
4.6.2 Future Strategies of the PHOENIX Group: Selective Acquisition
4.6.3 The PHOENIX Group: Revenue Forecast, 2018-2028
4.7 SINOPHARM: The Leading Pharmaceutical Wholesaler and Distributor in China
4.7.1 SINOPHARM: Historical Performance, 2011-2017
4.7.2 Future Strategies of SINOPHARM: Provide Comprehensive Services and Wider Business Coverage
4.7.3 SINOPHARM: Revenue Forecast, 2018-2028
4.8 Alfresa Holdings: Second Largest Pharmaceutical Wholesaler and Distributor in Japan
4.8.1 Alfresa Holdings: Historical Performance, 2011-2017
4.8.2 Future Strategy of Alfresa Holdings: To Focus on Expanding Business Fields and Increasing Footprint
4.8.3 Alfresa Holdings: Revenue Forecast, 2018-2028
4.9 SUZUKEN CO., LTD: The First Nationwide Wholesaler of Japan
4.9.1 SUZUKEN CO. LTD: Historical Performance, 2011-2017
4.9.2 Future Strategies of SUZUKEN CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field
4.9.3 SUZUKEN CO., LTD: Revenue Forecast, 2018-2028
4.10 Shanghai Pharmaceuticals Holding: China’s Second Largest Wholesaler
4.10.1 Shanghai Pharmaceuticals Holding: Historical Performance, 2011-2017
4.10.2 Future Strategies of Shanghai Pharma: Expansion of Three Leading Regions in China
4.10.3 Shanghai Pharma: Revenue Forecast, 2018-2028
4.11 Morris & Dickson Co. LLC: Serving More than 175 Years
4.12 H.D. Smith: Largest Independent Wholesaler in the U.S.
4.12.1 H.D. Smith Company History:
4.12.2 H.D. Smith Company Business Strategies
4.13 Smith Drug Company: Serving More than 1400 Customers in U.S.
4.14 Anda Inc.
4.14.1 Segment Overview
4.14.2 Anda Inc. Strategies
4.15 CuraScript Specialty Distribution
4.15.1 Curascript Speciality Distribution Strategies:
4.16 Mawdsley-Brooks & Co. Ltd.
4.16.1 Mawdsley-Brooks & Co Company History:
4.16.2 Mawdsley-Brooks & Co Company Strategies
4.17 North Carolina Mutual Wholesale Drug: 65 years of service
4.17.1 Mutual Wholesale Drug Company History:
4.17.2 Company Strategies
4.18 Prodigy Health
4.19 Fortissa Limited: 20 years of vast experience
4.20 CR Pharmaceutical
4.20.1 Company History
4.20.2 Company Strategies

5. Qualitative Analysis of The Pharma Wholesale and Distribution Market
5.1 The Strengths and Weaknesses of the Pharma Wholesale and Distribution Market, 2016
5.1.1 The Insatiable Demand for Drugs: A Recession Proof Industry?
5.1.2 Wholesalers Do More than Deliver Drugs
5.1.2.1 Pre-Wholesaling: More Prevalent in Europe
5.1.2.2 Through Pre-Financing, Full-Line Wholesalers Finance the Entire Medicines Market
5.1.3 Large Companies Dominate the Market
5.1.4 Despite High Revenues, Profit Margins Are Low
5.1.5 Government-Induced Drug Price Pressures Restrict Profits
5.1.6 The Problem of Counterfeit Drugs
5.2 The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2016-2027
5.2.1 The Demand for Pharmaceuticals is Increasing
5.2.2 The Increasing Use of Specialty Drugs Will Drive Growth
5.2.3 The Increasing Use of Generic Drugs Will Limit Revenue, But Drive Profit Generation
5.2.4 The Promotion of Drug Therapy in the US
5.2.5 Globalisation: The Major National Markets are Dominated by Few Companies
5.2.6 Increased Adoption of the DTP Distribution Model
5.2.6.1 DTP in Europe: The First Place the Scheme Has Taken Hold
5.2.6.2 DTP in the UK Since 1991
5.2.6.3 DTP in Poland: The Second European Country to Adopt the DTP Model
5.2.6.4 Further Expansion of the DTP Model
5.2.7 The Threat of Healthcare Budget Cuts
5.2.7.1 Healthcare Budget Cuts in Germany
5.2.7.2 Healthcare Budget Cuts in France
5.2.7.3 Healthcare Budget Cuts in Italy
5.2.7.4 Healthcare Budget Cuts in Spain
5.2.7.5 Healthcare Budget Cuts in the UK
5.2.8 Do Large Pharmacy Chains Pose a Threat?
5.2.8.1 Case Study: Walmart and the $4 Prescription Scheme
5.2.8.2 Vertical Integration of Wholesalers: A Response to the Threat of Pharmacy Chains
5.2.9 Does the Diversion and Re-Importation of Medicines Pose a Threat to the Industry?
5.2.10 The Threat of Industry Consolidation
5.3 Social, Technological, Economic and Political Factors Influencing the Market, 2016-2027 (STEP Analysis)
5.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU
5.3.2 Political Factor: Combating Counterfeit Medicines
5.3.2.1 The US and E-Pedigree: Becoming Law in California
5.3.2.2 European Pedigree Legislation
5.3.2.3 Anti-Counterfeiting Strategies in Other Markets: The Chinese Government is Attempting to Address the Challenge
5.3.2.4 Serialisation for Wholesalers: Opportunity or a Challenge?

6. Conclusions
6.1 The Future of the Pharma Wholesale and Distribution Market
6.2 The Leading National Pharma Wholesale and Distribution Markets
6.3 The Leading Companies in the Pharma Wholesale and Distribution Industry
6.4 Trends in the Pharma Wholesale and Distribution Industry
6.4.1 Generics Will Threaten Revenue
6.4.2 Manufacturers Will Deliver More Drugs Directly
6.4.3 There Will Be Greater Demand for Specialty Medicines
6.4.4 Consolidation Will Drive Growth
6.4.5 Anti-Counterfeiting Demands Will Add to Wholesalers’ Costs

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 2.1 Use of DTP Model in the UK 2007-2012
Table 3.1 Pharmaceutical Wholesale and Distribution: World Market Forecast ($bn), AGR (%), CAGR (%), 2016-2027
Table 3.2 Pharmaceutical Wholesale and Distribution: Branded Drugs, Generic Drugs and Others, Revenue ($bn) Forecasts, AGR (%), CAGR (%) and Market Shares (%), 2016-2027
Table 3.3 Wholesale and Distribution of Branded Drugs: Revenue ($bn) Forecasts, AGR (%), CAGR (%), 2016-2027
Table 3.4 Wholesale and Distribution of Generic Drugs: Revenue ($bn) Forecasts, AGR (%), CAGR (%), 2016-2027
Table 4.1 Mckesson, Distribution Solutions: Services and Customers, 2018
Table 4.2 Mckesson, Technology Solutions: Services and Customers, 2018
Table 4.3 Mckesson: Historical Revenue ($Bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($Bn), Gross Profit AGR (%) And Gross Profit CAGR (%), 2007-2017
Table 4.4 Mckesson Revenue ($Bn), Revenue Share (%) And AGR (%) Breakdown by Business Segment, 2017-2018
Table 4.5 Mckesson: Gross Profit ($Bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2017-2018
Table 4.6 Acquisitions by Mckesson, 2007-2018
Table 4.7 Mckesson: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2023
Table 4.8 Mckesson: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2023-2028
Table 4.9 Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Operating Earnings ($bn), AGR (%) and CAGR (%), 2007-2017
Table 4.10 Cardinal Health: Revenue ($Bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 4.11 Cardinal Health: Operating Earnings ($bn) And Annual Growth (%) Breakdown by Business Segment, 2016-2017
Table 4.12 Cardinal Health: Revenue ($bn) And Revenue Share (%) Breakdown by Customer, 2017
Table 4.13 Selected Acquisitions by Cardinal Health and their Line of Business, 2007-2017
Table 4.14 Cardinal Health: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2023
Table 4.15 Cardinal Health: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2023-2028
Table 4.16 Amerisourcebergen: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Operating Income ($bn), Operating Income AGR (%) and Operating Income CAGR (%), 2007-2017
Table 4.17 Amerisourcebergen: Revenue ($bn), Revenue Share (%) And AGR (%) Breakdown by Business Segment, 2016-2017
Table 4.18 Amerisourcebergen: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 4.19 Amerisourcebergen: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2017
Table 4.20 Acquisitions by AmerisourceBergen and their Line of Business, 2007-2017
Table 4.21 Amerisourcebergen: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2023
Table 4.22 Amerisourcebergen: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2023-2028
Table 4.23 Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2017
Table 4.24 Walgreens Boots Alliance: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2023
Table 4.25 Walgreens Boots Alliance: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2023-2028
Table 4.26 Medipal Holdings: Consolidated Subsidiary Companies, 2016
Table 4.27 Medipal Holdings: Historical Revenue (\bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit AGR (%), 2007-2017
Table 4.28 Medipal Holdings: Revenue (\bn) And AGR (%) Breakdown by Business Segment, 2016-2017
Table 4.29 Medipal Holdings: Operating Profit (\bn), And AGR (%) Breakdown by Business Segment, 2016-2017
Table 4.30 Medipal Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2023
Table 4.31 Medipal Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2023-2028
Table 4.32 Phoenix Group: Subsidiary Companies, 2018
Table 4.33 Phoenix Group: Historical Revenue (€bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (€bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2017
Table 4.34 Phoenix Group: Revenue Share (%) Breakdown by Region, 2016-2017
Table 4.35 Phoenix Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2023
Table 4.36 Phoenix Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2023-2028
Table 4.37 Sinopharm Group: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2017
Table 4.38 Sinopharm Group: Revenue (RMBbn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 4.39 Sinopharm Group: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 4.40 Sinopharm Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2023
Table 4.41 Sinopharm Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2023-2028
Table 4.42 Alfresa Holdings: List of Significant Subsidiaries and Affiliates, 2017
Table 4.43 Alfresa Holdings: Historical Revenue (\bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (\bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2017
Table 4.44 Alfresa Holdings: Business Strategies, 2013-2016
Table 4.45 Alfresa Holdings: Revenue (\bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 4.46 Alfresa Holdings: Revenue ($Bn), AGR (%) and CAGR (%) Forecast, 2017-2023
Table 4.47 Alfresa Holdings: Revenue ($Bn), AGR (%) and CAGR (%) Forecast, 2023-2028
Table 4.48 Suzuken: Historical Revenue (\bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (\bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2011-2017
Table 4.49 Suzuken: Revenue (\bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 4.50 Suzuken: Operating Income (\bn, $bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2016-2017
Table 4.51 Suzuken: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2023
Table 4.52 Suzuken: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2023-2028
Table 4.53 Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), 2011-2017
Table 4.54 Shanghai Pharmaceuticals Holding: Revenue (RMBbn, $bn), Revenue Share (%) And AGR (%) Breakdown by Business Segment, 2016-2017
Table 4.55 Shanghai Pharmaceuticals: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2017-2023
Table 4.56 Shanghai Pharmaceuticals: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2023-2028
Table 4.57 Morris & Dickson Co. LLC Profile 2018
Table 4.58 H.D. Smith Profile 2018
Table 4.59 Smith Drug Company Profile 2018
Table 4.60 Anda, Inc. Profile 2018
Table 4.61 Curascript Specialty Distribution. Profile 2018
Table 4.62 Mawdsley-Brooks & Co. Ltd. Profile 2018
Table 4.63 North Carolina Mutual Wholesale Drug Profile 2018
Table 4.64 Prodigy Health Profile 2018
Table 4.65 Fortissa Limited Profile 2018
Table 4.66 Cr Pharmaceutical Profile 2018
Table 5.1 The Pharmaceutical W&D Market: Strengths and Weaknesses
Table 5.2 The Pharmaceutical W&D Market: Opportunities and Threats
Table 5.3 Strengths and Weaknesses of The DTP Distribution Model
Table 5.4 ITR Ratings and Corresponding Reimbursement Rates, 2016
Table 5.5 Social, Technological, Economic and Political Factors Influencing the Pharmaceutical Wholesale and Distribution Market (Step Analysis), 2016-2027

List of Figures
Figure 2.1 Routes of Drug Distribution, 2016
Figure 3.1 The Global Pharmaceutical Wholesale and Distribution Market: Drivers and Restraints, 2017
Figure 3.2 Pharmaceutical Wholesale and Distribution: World Market Forecast ($bn), 2016-2027
Figure 3.3 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2016
Figure 3.4 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2021
Figure 3.5 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2027
Figure 3.6 Wholesale and Distribution of Branded Drugs, Generic Drugs and Others: Revenue Forecasts ($bn), 2016-2027
Figure 3.7 Wholesale and Distribution of Branded Drugs: Revenue ($bn) Forecast, 2016-2027
Figure 3.8 Wholesale and Distribution of Generic Drugs: Revenue ($bn) Forecast, 2016-2027
Figure 4.1 Mckesson: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) And Gross Profit AGR (%), 2007-2017
Figure 4.2 Mckesson: Revenue Share (%) Breakdown by Business Segment, 2018
Figure 4.3 Mckesson: Gross Profit Share (%) Breakdown by Business Segment, 2018
Figure 4.4 Mckesson: Revenue ($bn) Forecast, 2017-2028
Figure 4.5 Mckesson: Drivers and Restraints, 2018
Figure 4.6 Cardinal Health: Historical Revenue ($Bn), Revenue AGR (%), Operating Earnings ($bn) and Operating Earnings AGR (%), 2010-2015
Figure 4.7 Cardinal Health: Revenue Share (%) Breakdown by Business Segment, 2017
Figure 4.8 Cardinal Health: Revenue Share (%) Breakdown by Customer, 2017
Figure 4.9 Cardinal Health: Revenue ($bn) Forecast, 2018-2028
Figure 4.10 Cardinal Health: Drivers and Restraints, 2018
Figure 4.11 Amerisourcebergen: Historical Revenue ($bn), Revenue AGR (%), Operating Income ($bn) And Operating Income AGR (%), 2007-2017
Figure 4.12 Amerisourcebergen: Revenue Share (%) Breakdown by Business Segment, 2017
Figure 4.13 Amerisourcebergen: Revenue ($bn) Breakdown by Customer, 2017
Figure 4.14 Amerisourcebergen: Revenue ($bn) Forecast, 2017-2028
Figure 4.15 Amerisourcebergen: Drivers and Restraints, 2018
Figure 4.16 Walgreens Boots Alliance: Revenue ($Bn), Revenue AGR (%), Gross Profit ($bn) And Gross Profit AGR (%), 2011-2017
Figure 4.17 Walgreens Boots Alliance: Revenue ($bn) Forecast, 2017-2028
Figure 4.18 Walgreens Boots Alliance: Drivers and Restraints, 2018
Figure 4.19 Medipal Holdings: Historical Revenue (\Bn), Revenue AGR (%), and Gross Profit AGR (%), 2007-2017
Figure 4.20 Medipal Holdings: Revenue Share (%) Breakdown by Business Segment, 2017
Figure 4.21 Medipal Holdings: Operating Income Share (%) Breakdown by Business Segment, 2017
Figure 4.22 Medipal Holdings: Revenue ($bn) Forecast, 2017-2028
Figure 4.23 Medipal Holdings: Drivers and Restraints, 2018
Figure 4.24 Phoenix Group: Historical Revenue (€Bn), Revenue AGR (%), Gross Profit (€bn) And Gross Profit AGR (%), 2011-2017
Figure 4.25 Phoenix Group: Revenue Share (%) Breakdown by Region, 2017
Figure 4.26 Phoenix Group: Revenue ($bn) Forecast, 2017-2028
Figure 4.27 Phoenix Group Drivers and Restraints, 2018
Figure 4.28 Sinopharm Group: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) And Gross Profit AGR (%), 2011-2016
Figure 4.29 Sinopharm Group: Revenue ($bn) Forecast, 2017-2028
Figure 4.30 Sinopharm Group: Drivers and Restraints, 2018
Figure 4.31 Alfresa Holdings: Historical Revenue (\bn), Revenue AGR (%), Gross Profit (\bn), Gross Profit AGR (%), 2011-2017
Figure 4.32 Alfresa Holdings: Revenue Share (%) Breakdown by Business Segment, 2017
Figure 4.33 Alfresa Holdings: Revenue ($bn) Forecast, 2017-2028
Figure 4.34 Alfresa Holdings: Drivers and Restraints, 2018
Figure 4.35 Suzuken: Historical Revenue (\bn), Revenue AGR (%), Gross Profit (\bn) And Gross Profit AGR (%), 2011-2017
Figure 4.36 Suzuken: Revenue Share (%) Breakdown by Business Segment, 2017
Figure 4.37 Suzuken: Operating Income Share (%) Breakdown by Business Segment, 2017
Figure 4.38 Suzuken: Revenue ($bn) Forecast, 2017-2028
Figure 4.39 Suzuken: Drivers and Restraints, 2018
Figure 4.40 Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn), Revenue AGR (%), 2011-2017
Figure 4.41 Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Business Segment, 2017
Figure 4.42 Shanghai Pharmaceuticals Holding: Revenue ($bn) Forecast, 2018-2028
Figure 4.43 Shanghai Pharmaceuticals Holding: Drivers and Restraints, 2018
Figure 5.1 Comparison of The Wholesale and DTP Routes of Distribution, 2016
Figure 6.1 Pharmaceutical Wholesale and Distribution: Global Market Forecasts ($bn) By Submarket, 2016-2027
Figure 6.2 Leading National Pharmaceutical Wholesale and Distribution Markets: Revenue Projections ($Bn), 2016, 2021 And 2027
Figure 6.3 Leading Pharmaceutical Wholesale and Distribution Companies: Revenue ($bn) Projections 2016, 2021 and 2027

発刊日

2018/10/03

体裁

PDF / 229ページ

販売価格

2,699GBP

発行

Visiongain

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。
※シングルユーザーライセンスのレポートは印刷不可、およびライセンス期間は1年となります。
※印刷可能のレポートをご希望の場合は、デパートメントライセンス(ライセンス期間1年、ユーザー数5人)をご検討ください。
※詳しくはお問い合わせください。

関連カテゴリ

アウトソーシング

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE